Ofatumumab targets the same cells for depletion as Ocrelizumab and Rituximab, but it's not an infusion medication. Instead ofatumumab is self-injected monthly under the skin.

Another advantage is that “ofatumumab is a fully human antibody molecule unlike a chimeric or humanized molecule that has some mouse protein,” as do Ocrevus and rituximab. It’s argued that this could potentially lower the chance that patients will develop antibodies against the medicine, known as anti-drug antibodies, which decrease a treatment’s effectiveness over time.

“Ofatumumab shuts down new focal inflammatory activity nearly completely. It reduces relapse-independent disability progression, and at least in the clinical trial data to date, it has a very favorable safety profile. I believe that clinicians should consider the use of highly effective therapy with an agent like ofatumumab very early in the disease course,” said Hauser, who is a professor of neurology and the director of the University of California, San Francisco (UCSF) Weill Institute for Neurosciences.

Furthermore, “even though these three monoclonal antibodies, and a fourth called ublituximab, currently in development, are all targeting CD20, they target different regions of the CD20 molecule and neutralize B-cells in overlapping but different ways. So these drugs are not true biosimilars and should not be assumed to be equivalent,” Hauser said.

Full article: https://multiplesclerosisnewstoday.c...tumumab-data/?